Based on moderate quality evidence , due to concerns about risk of bias and imprecision , initiation of statin therapy within 14 days following ACS does not reduce death , myocardial infa rct ion , or stroke up to four months , but reduces the occurrence of unstable angina at four months following ACS .
Serious side effects were rare
BACKGROUND The early period following the onset of acute coronary syndrome ( ACS ) represents a critical stage of coronary heart disease , with a high risk of recurrent events and deaths .
The short-term effects of early treatment with statins on patient-relevant outcomes in patients suffering from ACS are unclear .
This is an up date of a review previously published in 2011 .
OBJECTIVES To assess the effects , both harms and benefits , of early administered statins in patients with ACS , in terms of mortality and cardiovascular events .
The effect of statin therapy on ventricular late potentials in acute myocardial infarction.
AIMS To determine whether early statin therapy in acute myocardial infa rct ion has any effect on ventricular late potentials which are considered as a noninvasive tool for evaluation of arrhythmogenic substrate . METHODS AND RESULTS Study population consisted of prospect ively enrolled 72 patients presenting with acute myocardial infa rct ion ( < 6 h ) . Thirty-four of the patients were r and omized to pravastatin ( 40 mg/day ) on admission irrespective of lipid levels . All patients received thrombolytic therapy .  Signal-averaged ECG recordings were obtained serially prior to thrombolytic therapy , 48 h after and 10 days later . Late potentials were defined as positive if signal-averaged ECG met at least two of Gomes criteria : filtered total QRS duration > 114 ms , root mean square voltage of the last 40 ms of the QRS < 20 mV , or the duration of the terminal low ( < 40 mV ) amplitude signals > 38 ms . Changes observed in signal-averaged ECG recordings after thrombolysis were evaluated statistically with regard to statin usage . There were no significant differences between the clinical characteristics of the two r and omized groups . There was a significant decrease in the rates of late potentials between the first and third signal-averaged ECG recordings after thrombolytic therapy in pravastatin group . Pravastatin group also had lower incidence of ventricular arrhythmias compared with control group ( 26 vs. 63 % , P=0.021 ) . The in-hospital cardiovascular event rates were also lower in statin group . CONCLUSION Early use of pravastatin reduces the incidence of late potentials following thrombolytic therapy in acute myocardial infa rct ion . Statin therapy also seems to be reducing the incidence of in-hospital ventricular arrhythmias . These beneficial effects of statins might be explained through prevention of new myocardial ischemic episodes due to early plaque stabilization or regulation of endothelial and platelet functions
Based on moderate quality evidence , due to concerns about risk of bias and imprecision , initiation of statin therapy within 14 days following ACS does not reduce death , myocardial infa rct ion , or stroke up to four months , but reduces the occurrence of unstable angina at four months following ACS .
Serious side effects were rare
BACKGROUND The early period following the onset of acute coronary syndrome ( ACS ) represents a critical stage of coronary heart disease , with a high risk of recurrent events and deaths .
The short-term effects of early treatment with statins on patient-relevant outcomes in patients suffering from ACS are unclear .
This is an up date of a review previously published in 2011 .
OBJECTIVES To assess the effects , both harms and benefits , of early administered statins in patients with ACS , in terms of mortality and cardiovascular events .